Bruch, Peter-Martin
Dietrich, Sascha http://orcid.org/0000-0002-0648-1832
Finel, Herve
Boumendil, Ariane
Greinix, Hildegard http://orcid.org/0000-0002-2780-3300
Heinicke, Thomas http://orcid.org/0000-0002-4049-7854
Bethge, Wolfgang http://orcid.org/0000-0001-6052-2618
Beelen, Dietrich http://orcid.org/0000-0001-5050-220X
Schmid, Christoph http://orcid.org/0000-0001-7070-487X
Martin, Hans
Castagna, Luca http://orcid.org/0000-0002-6239-7387
Scheid, Christof
Schäfer-Eckart, Kerstin
Bittenbring, Jörg
Finke, Jürgen
Sengeloev, Henrik
Heiblig, Mael http://orcid.org/0000-0003-1682-8657
Cornelissen, Jan
Chevallier, Patrice
Mohty, Mohamad
Robinson, Stephen
Montoto, Silvia
Dreger, Peter
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (SYMPATHY, CompLS project MOFA under grant agreement number 031L0171A)
Deutsche Forschungsgemeinschaft (SFB873)
Else Kröner Fresenius Foundation
Article History
Received: 28 August 2022
Revised: 23 November 2022
Accepted: 25 November 2022
First Online: 22 December 2022
Competing interests
: PD: consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. SD: consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Gilead and Janssen. P-MB: speakers bureau for AstraZeneca. TH: consultancy Eurocept, travel grants from Jazz, Gilead, Eurocept and Daichii. All other authors declare no conflict of interest.